Kite Pharma, Inc.
KITE
KITE was delisted on the 2nd of October, 2017.
184 hedge funds and large institutions have $2B invested in Kite Pharma, Inc. in 2016 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 81 increasing their positions, 47 reducing their positions, and 41 closing their positions.
72% more repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 47
6% less funds holding
Funds holding: 195 → 184 (-11)
7% less capital invested
Capital invested by funds: $2.16B → $2B (-$156M)
20% less first-time investments, than exits
New positions opened: 33 | Existing positions closed: 41
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
51% less call options, than puts
Call options by funds: $18.7M | Put options by funds: $38M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$49.7M |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
+$29.2M |
| 3 |
Jennison Associates
New York
|
+$24.9M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$24.3M |
| 5 |
BII
Bainco International Investors
Boston,
Massachusetts
|
+$23.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
-$28.9M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$17.6M |
| 3 |
DP
DSAM Partners
London,
United Kingdom
|
-$6.32M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$5.04M |
| 5 |
Zurich Cantonal Bank
Zurich,
Switzerland
|
-$4.65M |
KITE Hedge Fund Activity: Q4 2016 in Review
184 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Kite Pharma, Inc. (KITE) for Q4 2016, worth a combined $2B — down 7.2% from $2.16B a quarter earlier.
Sellers outnumbered buyers: 41 funds closed out of KITE and 33 opened new positions — a net loss of 8 holders — while 47 trimmed existing stakes and 81 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $49.7M. The largest seller was Viking Global Investors, exiting entirely with an estimated $28.9M sold.
- 184 institutional investors held Kite Pharma, Inc. (KITE) as of Q4 2016, down from 195 in Q3 2016.
- Funds reported $2B of Kite Pharma, Inc. stock for Q4 2016, down 7.2% quarter-over-quarter.
- 33 funds opened new Kite Pharma, Inc. positions in Q4 2016 and 41 closed out, a net change of -8 holders.
- The largest Kite Pharma, Inc. buyer in Q4 2016 was T. Rowe Price Associates, an estimated $49.7M added.
- The largest Kite Pharma, Inc. seller in Q4 2016 was Viking Global Investors, an estimated $28.9M sold.
Based on aggregated 13F filings for Q4 2016.